In the Literature

Patients with diffuse large B-cell lymphoma (DLBCL) who have not responded to available therapies, with relapsed or primary resistant disease, have a poor prognosis.
Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. In a recent study, researchers evaluated the efficacy of upfront maintenance therapy with olaparib in patients with newly diagnosed, advanced BRCA-positive ovarian cancer.
Chemoimmunotherapy with chlor­ambucil plus obinutuzumab or bendamustine plus rituximab is standard frontline treatment for older patients with chronic lymphocytic leukemia (CLL). However, chemoimmunotherapy is associated with toxic effects, and the risk increases with age. For patients with CLL, frontline ibrutinib monotherapy is widely used in clinical practice. The benefit of this Bruton’s tyrosine kinase (BTK) inhibitor versus standard chemoimmunotherapy remains a critical consideration, which led researchers to conduct a head-to-head phase 3 study to evaluate the efficacy of ibrutinib, either alone or in combination with rituximab, relative to chemoimmunotherapy.
  • Ixazomib Extends Progression-Free Survival in Multiple Myeloma
  • Pembrolizumab Shows Potential Antitumor Activity in Advanced Gastric Cancer
  • ASCO Endorses Canadian Clinical Practice Guideline on Active Surveillance for Localized Prostate Cancer
  • Delayed Relapses After Anti–PD-1 Therapy Linked to Mutation in Patients with Melanoma

Results 1 - 4 of 4
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME